-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $60

Benzinga·01/05/2026 17:17:07
语音播报
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $80 to $60.